These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 12084061)

  • 21. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion.
    Csati A; Tajti J; Kuris A; Tuka B; Edvinsson L; Warfvinge K
    Neuroscience; 2012 Jan; 202():158-68. PubMed ID: 22108610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology.
    Wei Y; Mojsov S
    J Neuroendocrinol; 1996 Nov; 8(11):811-7. PubMed ID: 8933357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectivity and efficacy.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Robberecht P
    Int J Pept Protein Res; 1996 Oct; 48(4):391-6. PubMed ID: 8919060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
    Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
    J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
    Moody TW; Jensen RT; Fridkin M; Gozes I
    J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
    Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
    J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pituitary adenylate cyclase-activating peptide stimulates acute progesterone production in rat granulosa/Lutein cells via two receptor subtypes.
    Gräs S; Hedetoft C; Pedersen SH; Fahrenkrug J
    Biol Reprod; 2000 Jul; 63(1):206-12. PubMed ID: 10859261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
    Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
    J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of second extracellular loop in the function of human vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide receptor 1 (hVPAC1R).
    Knudsen SM; Tams JW; Fahrenkrug J
    J Mol Neurosci; 2000 Jun; 14(3):137-46. PubMed ID: 10984189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
    Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
    Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
    Tsutsumi M; Claus TH; Liang Y; Li Y; Yang L; Zhu J; Dela Cruz F; Peng X; Chen H; Yung SL; Hamren S; Livingston JN; Pan CQ
    Diabetes; 2002 May; 51(5):1453-60. PubMed ID: 11978642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
    Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M; Ganea D
    J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor.
    Uchida D; Tatsuno I; Tanaka T; Hirai A; Saito Y; Moro O; Tajima M
    Ann N Y Acad Sci; 1998 Dec; 865():253-8. PubMed ID: 9928019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural characterization of PACAP receptors on rat liver plasma membranes.
    Nguyen TD; Heintz GG; Wolfe MS
    Am J Physiol; 1993 Nov; 265(5 Pt 1):G811-8. PubMed ID: 8238511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP.
    Laburthe M; Couvineau A
    Regul Pept; 2002 Oct; 108(2-3):165-73. PubMed ID: 12220741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maxadilan specifically interacts with PAC1 receptor, which is a dominant form of PACAP/VIP family receptors in cultured rat cortical neurons.
    Tatsuno I; Uchida D; Tanaka T; Saeki N; Hirai A; Saito Y; Moro O; Tajima M
    Brain Res; 2001 Jan; 889(1-2):138-48. PubMed ID: 11166697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ageing and the diurnal expression of mRNAs for vasoactive intestinal peptide and for the VPAC2 and PAC1 receptors in the suprachiasmatic nucleus of male rats.
    Kalló I; Kalamatianos T; Piggins HD; Coen CW
    J Neuroendocrinol; 2004 Sep; 16(9):758-66. PubMed ID: 15344914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
    Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
    J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.